Significantly higher peripheral fibroblast growth factor-2 levels in patients with major depressive disorder: A preliminary meta-analysis under MOOSE guidelines
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In vivo and in vitro studies demonstrate the important roles of fibroblast growth factor (FGF) and FGF receptors (FGFRs) in neural survival, neurogenesis, oxidative stress, and emotional behavior. However, evidence on the role of FGF and FGFR in the pathophysiology of major depressive disorder (MDD) remains limited and inconclusive. OBJECTIVES: This preliminary meta-analysis aimed to examine changes in peripheral or central FGF and FGFR levels in patients with MDD. DATA SOURCES: Electronic research through platform of PubMed and ClinicalTrials.gov. STUDY ELIGIBILITY CRITERIA, PARTICIPANTS, AND INTERVENTIONS: We used the inclusion criteria: articles discussing the comparisons of FGF levels, either in peripheral or central environment, in patients with MDD and in healthy controls (HC); articles on clinical trials in humans; and case-control trials. Case reports or series and nonclinical trials were excluded. STUDY APPRAISAL AND SYNTHESIS METHODS: Using a thorough literature search, the FGF/FGFR levels in patients with MDD and HC were compared. Four studies on peripheral FGF-2 and 3 on central FGF-2 and FGFR1 levels were included. RESULTS: The findings reveal significantly higher peripheral FGF-2 protein and central FGFR1 RNA levels in patients with MDD than in HC (P = 0.005 and 0.006, separately), but no significant association with clinical variables. There was also no significant difference in the central FGF-2 levels in patients with MDD and in HC (P = 0.180). LIMITATION: The study has limitations of a small number of included studies, lack of meta-analysis of the FGF changes along with treatment, and lack of direct evidence on correlation of peripheral FGF-2 with central FGF-2 levels. CONCLUSIONS AND IMPLICATIONS OF KEY FINDINGS: This preliminary meta-analysis points out a new direction for future studies investigating the relationship among MDD, oxidative stress, and the FGF family.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206
Dysregulation of the fibroblast growth factor system in major depression
Evans, S. J., Choudary, P. V., Neal, C. R., Li, J. Z., Vawter, M. P., Tomita, H., Lopez, J. F., Thompson, R. C., Meng, F., Stead, J. D., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406788101 · Cited by 424
Fibroblast Growth Factors In The Developing Central Nervous System
Ford‐Perriss, M., Abud, H., & Murphy, M. (2001) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2001.03477.x · Cited by 264 · cited 1×
“Studyappraisal andsynthesismethods:Using a thorough literature search, the FGF/FGFR levels in patients with MDD and HC were compared.”
Najjar, S., Pearlman, D. M., Devinsky, O., Najjar, A., & Zagzag, D. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-142 · Cited by 248
Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder
Gaughran, F., Payne, J., Sedgwick, P. M., Cotter, D., & Berry, M. (2006) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.04.008 · Cited by 178
Zhao, M., Li, D., Shimazu, K., Zhou, Y.-X., Lu, B., & Deng, C.-X. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.10.019 · Cited by 171
The Fibroblast Growth Factor Family: Neuromodulation of Affective Behavior
Turner, C. A., Watson, S. J., & Akil, H. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.037 · Cited by 160
Depression and employment status in primary and tertiary care settings
Rizvi, S. J., Cyriac, A., Grima, E., Tan, M., Lin, P., Gallaugher, L. A., McIntyre, R. S., & Kennedy, S. H. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000105 · Cited by 80 · cited 1×
“Objectives:This preliminary meta-analysis aimed to examine changes in peripheral or central FGF and FGFR levels in patients with MDD. Data sources: Electronic research through platform of PubMed and ClinicalTrials.gov.”
Self-citation
Cited by
Biomarkers for depression: recent insights, current challenges and future prospects
Strawbridge, R., Young, A. H., & Cleare, A. J. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114542 · Cited by 415
Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders
Carvalho, A. F., Solmi, M., Sanches, M., Machado, M. O., Stubbs, B., Ajnakina, O., Sherman, C., Sun, Y. R., Liu, C. S., Brunoni, A. R., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0835-5 · Cited by 204
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197
Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust
Kumar, A., Nader, M. A., & Deep, G. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000788 · Cited by 79
Xu, Y., Liang, J., Sun, Y., Zhang, Y., Shan, F., Ge, J., & Xia, Q. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110108 · Cited by 41
Metadata
- Authors
- Wu, C.-K., Tseng, P.-T., Chen, Y.-W., Tu, K.-Y., & Lin, P.-Y.
- Venue
- Medicine
- Published
- 2016-08
- Volume
- 95
- Issue
- 33
- Pages
- e4563
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2507219501
- Cited by
- 33
- References
- 8
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Significantly higher peripheral fibroblast growth factor-2 levels in patients with major depressive disorder: A preliminary meta-analysis under MOOSE guidelines. https://app.cochat.ai/papers/10.1097/md.0000000000004563
- The paper
- Wu, C.-K., Tseng, P.-T., Chen, Y.-W., Tu, K.-Y., & Lin, P.-Y. (2016). Significantly higher peripheral fibroblast growth factor-2 levels in patients with major depressive disorder: A preliminary meta-analysis under MOOSE guidelines. Medicine. https://doi.org/10.1097/md.0000000000004563
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.